covalent targeted affinity protein drugs (Affibody)
86
Structured Review
Affibody
covalent targeted affinity protein drugs
Covalent Targeted Affinity Protein Drugs, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covalent+targeted+affinity+protein+drugs/affinity+covalent+drugs+protein+targeted/pm41178218-25-5-13
Average 86 stars, based on 1 article reviews
Covalent Targeted Affinity Protein Drugs, supplied by Affibody, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/covalent+targeted+affinity+protein+drugs/affinity+covalent+drugs+protein+targeted/pm41178218-25-5-13
Average 86 stars, based on 1 article reviews
covalent targeted affinity protein drugs - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Construct:Article Title: Synergistic SuFEx-Driven Covalent Cancer Therapy Using a HER2/EGFR Bivalent Affinity Protein Drug. Article Snippet: The integration of sulfur fluoride exchange (SuFEx) chemistry into proteins is significantly advancing their applications in biological fields.. However, its suboptimal reaction rates in proteins limit the effectiveness of covalent crosslinking.. In this study, we develop a bivalent affinity protein drug by chemically coupling maleimide-substituted aryl fluorosulfate (MFS) linkers to a dual-targeting affinity protein drug that can covalently target both HER2 and EGFR. Activity Assay:Article Title: Synergistic SuFEx-Driven Covalent Cancer Therapy Using a HER2/EGFR Bivalent Affinity Protein Drug. Article Snippet: The integration of sulfur fluoride exchange (SuFEx) chemistry into proteins is significantly advancing their applications in biological fields.. However, its suboptimal reaction rates in proteins limit the effectiveness of covalent crosslinking.. In this study, we develop a bivalent affinity protein drug by chemically coupling maleimide-substituted aryl fluorosulfate (MFS) linkers to a dual-targeting affinity protein drug that can covalently target both HER2 and EGFR. |